Work Packages (WPs)
WP1 – FA metabolites from lipidomics as novel biomarkers of cardiometabolic health
WP1 will evaluate novel lipidomic markers as risk factors for cardiometabolic health/risk. Dietary FA intake is hypothesized to affect FA partitioning across different lipid families. The cardiometabolic risk will be investigated in terms of cross-sectional relationships between lipidomic markers and CVD risk factors as well as prospective analyses with regard to T2DM risk. Furthermore, we will investigate if relevant lipidomics markers can be modified by specific dietary interventions.
WP2 – Identification of FA biomarkers of dairy intake and their interaction with health markers
The objectives of WP2 are threefold:
- to use data from human FA intervention RCTs, that used dairy in dietary manipulation, to determine whether FA such as C15:0, C17:0 and trans-palmitoleic acid are biomarkers of dairy SFA intake;
- then to determine whether changes in these FA and other trans-FA, and SFA are related to cardiometabolic health/risk using both CVD and T2DM endpoint measures and risk biomarkers; and
- the lipidomic analysis will be performed (as described in WP1) and combined with phospholipid FA data to determine whether any novel biomarkers of cardiometabolic health include dairy SFA.
WP3 – Identification of genetic and dietary modulators of response to dietary FA intake
WP3 will evaluate genetic and dietary modulators of response to dietary FA intake. We will concentrate on the dietary intake of polyphenols as well as genetic variants involved in PUFA metabolism. These potential modulators are hypothesized to modify the response to dietary intake of FAs in terms of their effect on FA composition and cardiometabolic risk.